RTP Mobile Logo
This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders (eg, myelodysplastic syndromes, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 162,020 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2015 and 56,630 individuals will die from these diseases.

More than 60 drug products with more than 70 distinct FDA-approved indications are currently labeled for use in the management of hematologic cancers. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

These video proceedings from a CME symposium held during the 2015 ASCO Annual Meeting feature discussions with leading researchers with an expertise in hematologic cancers regarding actual patient cases and related clinical research findings. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to not only improve clinicians’ knowledge of recent data related to the rapidly evolving hematologic oncology treatment landscape but also to provide them with practical perspectives to help them become better and more effective caregivers.


  • Incorporate new therapeutic strategies into the best-practice management of Hodgkin lymphoma.
  • Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.
  • Consider available clinical research reports in the formulation of therapeutic recommendations for patients with newly diagnosed and relapsed/refractory follicular lymphoma.
  • Customize the selection of systemic therapy for patients with newly diagnosed and progressive mantle-cell lymphoma, recognizing the recent addition of bortezomib, lenalidomide and ibrutinib as FDA-endorsed options.
  • Appreciate the recent FDA approvals of novel targeted agents — ibrutinib, idelalisib and obinutuzumab — for the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia, and discern how these therapies can be appropriately integrated into clinical practice.
  • Recognize the role of novel agents in the management of T-cell lymphomas, and ensure appropriate supportive care measures to minimize side effects.
  • Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for newly diagnosed and relapsed/refractory multiple myeloma (MM).
  • Customize the use of consolidation and/or maintenance therapeutic approaches for patients with MM in the post-transplant and nontransplant settings based on patient- and disease-related factors.
  • Assess investigator perspectives regarding the need for hydration, the incidence of pulmonary and/or cardiac toxicity and the frequency of other side effects associated with carfilzomib, and safely integrate this agent into the clinical care of patients with MM.
  • Assess the ongoing clinical trials evaluating novel investigational approaches for Hodgkin and non-Hodgkin lymphoma and MM, and enroll appropriate patients in clinical trials.

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue


CME credit is no longer available for this issue

This CME activity consists of a video component.

CME credit is no longer available for this issue

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Stephen M Ansell, MD, PhD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, Minnesota

Contracted Research: Bristol-Myers Squibb Company, Celldex Therapeutics, Seattle Genetics.

Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

No real or apparent conflicts of interest to disclose.

Craig Moskowitz, MD
Clinical Director, Division of Hematologic Oncology
Attending Physician
Lymphoma and Adult BMT Services
Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College of Cornell University
New York, New York

Advisory Committee: Genentech BioOncology, Seattle Genetics; Contracted Research: Genentech BioOncology, GlaxoSmithKline, Merck, Seattle Genetics.

Antonio Palumbo, MD
Chief, Myeloma Unit
Division of Hematology
University of Torino
Torino, Italy

Advisory Committee and Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Amgen Inc, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

Jeff Sharman, MD
Director of Research
Willamette Valley Cancer Institute
Medical Director of Hematology Research
The US Oncology Network
Eugene, Oregon

Advisory Committee: Celgene Corporation, Gilead Sciences Inc, Pharmacyclics Inc; Consulting Agreement: Celgene Corporation; Contracted Research: Celgene Corporation, Cephalon Inc, Genentech BioOncology, Gilead Sciences Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics Inc, Takeda Oncology.

MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology, Onyx Pharmaceuticals, an Amgen subsidiary, Seattle Genetics and Takeda Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: October 2015
Expiration date: October 2016